Stay updated with breaking news from Chemotype Evolution. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EconoTimes is a fast growing non-partisan source of news and intelligence on global economy and financial markets, providing timely, relevant, and critical insights for market professionals and those who want to make informed investment decisions.
In addition to the GLP-1 assets, Roche will get access to Carmot’s research and development portfolio of clinical and pre-clinical assets.
Carmot Therapeutics isn’t the first company targeting both the GLP-1 and GIP receptors to treat metabolic diseases. But the company contends that biased signaling—activating certain pathways but not others—is key to setting its drugs apart from others in the same class.
The following stocks are the leading risers and fallers among London Main Market small-caps on Tuesday. ---------- SMALL-CAP - WINNERS ---------- Zotefoams PLC, up 3.7% at 353.64 pence, 12-month... | June 6, 2023
The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: ---------- Ethernity Networks Ltd - Israel-based supplier of data... | June 6, 2023